Futura Medical appoints Roy Davis as non-executive director

Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive director with immediate effect.

Davis brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted medtech companies, including CEO of Optos, a retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Davis was CEO of Gyrus Group, a specialist in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion.

He is currently non-executive chair at LungLife AI, Foster and Freeman and Rair Health and was until recently, non-executive chair at Medica Group until its acquisition by IK Partners for £269 million earlier this year. On 7th December, it was announced that Davis will become a non-executive director and chair designate of Inspiration Healthcare Group with effect from 25th January 2024.

Jeff Needham, chairman of Futura Medical said: “Roy brings with him significant commercial expertise and a proven track record of creating substantial shareholder value. His appointment will add to the depth and breadth of experience of the Futura Board as we continue to monetise our key asset, Eroxon, move towards profitability, and deliver on our strategy.”

Roy Davis, said: “I am delighted to be joining the Board of Futura. The Company is providing novel solutions in the sexual health sector and has exciting opportunities ahead of it. I look forward to working with the Board and Executive Team to help execute the strategy and deliver shareholder value.”